OPM achieved several major scientific and regulatory milestones as part of the LARKIN program, supported with funding by The Michael J. Fox Foundation for Parkinson’s Research (MJFF)

OPM achieved several major scientific and regulatory milestones as part of the LARKIN program, supported with funding by The Michael J. Fox Foundation for Parkinson’s Research (MJFF)

Dijon (France), October 7, 2026, at 6:00 p.m. CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine, today announced several strategic advances in the development of OPM-201, its LRRK2 kinase inhibitor for the treatment of Parkinson’s disease.

• MJFF confirms its support to the program with the payment of an additional funding tranche
• Successful micronization of the active pharmaceutical ingredient and manufacturing of the first technical batches of OPM-201 tablets
• European Medicines Agency (EMA) support for OPM’s proposed long-term toxicology strategy
• Preparation of the next regulatory and clinical development steps for OPM-201, with the objective of initiating a Phase 1b trial in patients with Parkinson’s disease in 2027